REFERENCES
1. Teede HJ, Misso ML, Boyle JA, Garad RM, McAllister V, Downes L, et al. Translation and implementation of the Australian-led PCOS guideline: clinical summary and translation resources from the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Med J Aust. 2018;209(S7):S3-S8.
2. Williams T, Mortada R, Porter S. Diagnosis and Treatment of Polycystic Ovary Syndrome. Am Fam Physician. 2016;94(2):106-13.
3. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet Gynecol. 2018;131(6):e157-e71.
4. Wang Y-Y, Li S-W, Luo S, Qin L, Zeng X, Li L, et al. How to Evaluate Acne in Reproductive-Age Women: An Epidemiological Study in Chinese Communities. Biomed Res Int. 2019;2019:6126808-.
5. Advani K, Batra M, Tajpuriya S, Gupta R, Saraswat A, Nagar HD, et al. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study. J Obstet Gynaecol. 2020;40(1):96-101.
6. Crespo RP, Bachega TASS, Mendonça BB, Gomes LG. An update of genetic basis of PCOS pathogenesis. Arch Endocrinol Metab. 2018;62(3):352-61.
7. Podfigurna A, Meczekalski B, Petraglia F, Luisi S. Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone). J Endocrinol Invest. 2019:10.1007/s40618-019-01133-3.
8. Moghetti P. Insulin Resistance and Polycystic Ovary Syndrome. Curr Pharm Des. 2016;22(36):5526-34.
9. Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019;92:108-20.
10. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME–PART 1. Endocr Pract. 2015;21(11):1291-300.
11. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006;91(3):781-5.
12. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88.
13. Gainder S, Sharma B. Update on Management of Polycystic Ovarian Syndrome for Dermatologists. Indian Dermatol Online J. 2019;10(2):97-105.
14. Witchel SF, Oberfield SE, Peña AS. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J Endocr Soc. 2019;3(8):1545-73.
15. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6-15.
16. Bienenfeld A, Azarchi S, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: Androgen-mediated skin disease and patient evaluation. J Am Acad Dermatol. 2019;80(6):1497-506.
17. Hacivelioglu S, Gungor ANC, Gencer M, Uysal A, Hizli D, Koc E, et al. Acne severity and the Global Acne Grading System in polycystic ovary syndrome. Int J Gynaecol Obstet. 2013;123(1):33-6.
18. Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R. Androgen excess: Investigations and management. Best Pract Res Clin Obstet Gynaecol. 2016;37:98-118.
19. Rocha MA, Bagatin E. Skin barrier and microbiome in acne. Arch Dermatol Res. 2018;310(3):181-5.
20. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016;37(5):467-520.
21. Witchel SF, Burghard AC, Tao RH, Oberfield SE. The diagnosis and treatment of PCOS in adolescents: an update. Curr Opin Pediatr. 2019;31(4):562-9.
22. Franik G, Bizoń A, Włoch S, Kowalczyk K, Biernacka-Bartnik A, Madej P. Hormonal and metabolic aspects of acne vulgaris in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2018;22(14):4411-8.
23. Kyritsi EM, Dimitriadis GK, Kyrou I, Kaltsas G, Randeva HS. PCOS remains a diagnosis of exclusion: a concise review of key endocrinopathies to exclude. Clin Endocrinol (Oxf). 2017;86(1):1-6.
24. Pasquali R. Contemporary approaches to the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2018;9(4):123-34.
25. Tan J, Boyal S, Desai K, Knezevic S. Oral Isotretinoin: New Developments Relevant to Clinical Practice. Dermatol Clin. 2016;34(2):175-84.
26. Al-Talib H, Al-Khateeb A, Hameed A, Murugaiah C. Efficacy and safety of superficial chemical peeling in treatment of active acne vulgaris. An Bras Dermatol. 2017;92(2):212-6.
27. Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. Endocr Rev. 2017;38(3):220-54.
28. Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol. 2011;3(1):41-9.
29. Morgante G, Massaro MG, Di Sabatino A, Cappelli V, De Leo V. Therapeutic approach for metabolic disorders and infertility in women with PCOS. Gynecol Endocrinol. 2018;34(1):4-9.
30. Powell A. Choosing the Right Oral Contraceptive Pill for Teens. Pediatr Clin North Am. 2017;64(2):343-58.
31. Jin P, Xie Y. Treatment strategies for women with polycystic ovary syndrome. Gynecol Endocrinol. 2018;34(4):272-7.
32. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364-79.
33. Del Rosso JQ, Harper JC, Graber EM, Thiboutot D, Silverberg NB, Eichenfield LF. Status report from the American Acne & Rosacea Society on medical management of acne in adult women, part 3: oral therapies. Cutis. 2015;96(6):376-82.
34. Roach REJ, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;2015(8):CD011054-CD.
35. Bitzer J, Römer T, Lopes da Silva Filho A. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. Eur J Contracept Reprod Health Care. 2017;22(3):172-82.
36. Calhoun AH. Hormonal Contraceptives and Migraine With Aura-Is There Still a Risk? Headache. 2017;57(2):184-93.
37. Calhoun AH, Batur P. Combined hormonal contraceptives and migraine: An update on the evidence. Cleve Clin J Med. 2017;84(8):631-8.
38. Lessner E, Fisher S, Kobraei K, Osleber M, Lessner R, Elliott L, et al. Spironolactone and topical retinoids in adult female cyclical acne. J Drugs Dermatol. 2014;13(2):126-9.
39. Basu P, Elman SA, Abudu B, Beckles A, Salian P, Yanes DA, et al. High-dose spironolactone for acne in patients with polycystic ovarian syndrome: a single institution retrospective study. J Am Acad Dermatol. 2019:S0190-9622(19)32497-1.
40. Chaudhary M, Chaudhary M. A REVIEW ON TREATMENT OPTIONS FOR ACNE VULGARIS. WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES. 2016;5:524-45.
41. Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. Am J Clin Dermatol. 2017;18(2):169-91.
42. Buzney E, Sheu J, Buzney C, Reynolds RV. Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment. J Am Acad Dermatol. 2014;71(5):859.e1-74.
43. Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol. 2015;200:25-9.
44. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73.e33.
45. Zouboulis CC, Bettoli V. Management of severe acne. Br J Dermatol. 2015;172 Suppl 1:27-36.
46. Acmaz G, Cınar L, Acmaz B, Aksoy H, Kafadar YT, Madendag Y, et al. The Effects of Oral Isotretinoin in Women with Acne and Polycystic Ovary Syndrome. Biomed Res Int. 2019;2019:2513067-.
47. Mirnezami M, Rahimi H. Is Oral Omega-3 Effective in Reducing Mucocutaneous Side Effects of Isotretinoin in Patients with Acne Vulgaris? Dermatol Res Pract. 2018;2018:6974045-.
48. Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther. 2017;30(4):10.1111/dth.12483.
49. Dathe K, Schaefer C. Drug safety in pregnancy: the German Embryotox institute. Eur J Clin Pharmacol. 2018;74(2):171-9.
50. Mendoza FJ, Serrano-Rodriguez JM, Buzon-Cuevas A, Perez-Ecija A. Pharmacokinetics of the anti-androgenic drug flutamide in healthy stallions. Vet J. 2017;224:50-4.
51. Husein-ElAhmed H. Management of acne vulgaris with hormonal therapies in adult female patients. Dermatol Ther. 2015;28(3):166-72.
52. Elsaie ML. Hormonal treatment of acne vulgaris: an update. Clin Cosmet Investig Dermatol. 2016;9:241-8.
53. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv Clin Exp Med. 2017;26(2):359-67.
54. Alexis A, Del Rosso JQ, Desai SR, Downie JB, Draelos ZD, Feser C, et al. BPX-01 Minocycline Topical Gel Shows Promise for the Treatment of Moderate-to-severe Inflammatory Acne Vulgaris. J Clin Aesthet Dermatol. 2018;11(11):25-35.
55. Del Rosso JQ. Oral Doxycycline in the Management of Acne Vulgaris: Current Perspectives on Clinical Use and Recent Findings with a New Double-scored Small Tablet Formulation. J Clin Aesthet Dermatol. 2015;8(5):19-26.
56. Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Womens Dermatol. 2017;4(2):56-71.
57. Barbieri JS, Hoffstad O, Margolis DJ. Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): A retrospective cohort study. J Am Acad Dermatol. 2016;75(6):1142-50.e1.
58. Farrah G, Tan E. The use of oral antibiotics in treating acne vulgaris: a new approach. Dermatol Ther. 2016;29(5):377-84.
59. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs. 2003;63(15):1579-96.
60. Sharma S, Mathur DK, Paliwal V, Bhargava P. Efficacy of Metformin in the Treatment of Acne in Women with Polycystic Ovarian Syndrome: A Newer Approach to Acne Therapy. J Clin Aesthet Dermatol. 2019;12(5):34-8.
61. Lee JK, Smith AD. Metformin as an adjunct therapy for the treatment of moderate to severe acne vulgaris. Dermatol Online J. 2017;23(11):13030/qt53m2q13s.
62. Robinson S, Kwan Z, Tang MM. Metformin as an adjunct therapy for the treatment of moderate to severe acne vulgaris: A randomized open-labeled study. Dermatol Ther. 2019;32(4):e12953-e.
63. Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017;19(4):473-81.
64. Li Y, Tan J, Wang Q, Duan C, Hu Y, Huang W. Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2020;113(1):197-204.
65. Fox L, Csongradi C, Aucamp M, du Plessis J, Gerber M. Treatment Modalities for Acne. Molecules. 2016;21(8):1063.
66. Sacchidanand SA, Lahiri K, Godse K, Patwardhan NG, Ganjoo A, Kharkar R, et al. Synchronizing Pharmacotherapy in Acne with Review of Clinical Care. Indian J Dermatol. 2017;62(4):341-57.
67. Latter G, Grice JE, Mohammed Y, Roberts MS, Benson HAE. Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems. Pharmaceutics. 2019;11(10):490.
68. Marson JW, Baldwin HE. An Overview of Acne Therapy, Part 1: Topical therapy, Oral Antibiotics, Laser and Light Therapy, and Dietary Interventions. Dermatol Clin. 2019;37(2):183-93.
69. Veraldi S, Rossi LC, Barbareschi M. Are topical retinoids teratogenic? G Ital Dermatol Venereol. 2016;151(6):700-5.
70. Cong T-X, Hao D, Wen X, Li X-H, He G, Jiang X. From pathogenesis of acne vulgaris to anti-acne agents. Arch Dermatol Res. 2019;311(5):337-49.
71. Leyden J, Stein-Gold L, Weiss J. Why Topical Retinoids Are Mainstay of Therapy for Acne. Dermatology and therapy. 2017;7(3):293-304.
72. Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther. 2016;7:13-25.
73. McKeage K, Keating GM. Clindamycin/benzoyl peroxide gel (BenzaClin): a review of its use in the management of acne. Am J Clin Dermatol. 2008;9(3):193-204.
74. Austin BA, Fleischer AB, Jr. The extinction of topical erythromycin therapy for acne vulgaris and concern for the future of topical clindamycin. J Dermatolog Treat. 2017;28(2):145-8.
75. Tripathi SV, Gustafson CJ, Huang KE, Feldman SR. Side effects of common acne treatments. Expert Opin Drug Saf. 2013;12(1):39-51.
76. Haroon MZ, Alam A, Ullah I, Ali R, Taimur MF, Raza K. Quality Of Life And Depression Among Young Patients Suffering From Acne. J Ayub Med Coll Abbottabad. 2019;31(3):436-40.
77. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84.
78. Cooper AJ, Harris VR. Modern management of acne. Med J Aust. 2017;206(1):41-5.